Table 3.
Multivariate analysis for PFS in patients undergoing laparoscopic scoring assessment
| HR (95% CI) | p-value | |
|---|---|---|
|
| ||
| Age at diagnosis | 1.02 (0.98-1.06) | 0.39 |
|
| ||
| ECOG status | 1.26 (0.82-1.93) | 0.29 |
|
| ||
| Charlson comorbidity index | 1.02 (0.84-1.22) | 0.87 |
|
| ||
| Baseline CA-125 | 1.00 (1.00-1.00) | 0.001 |
|
| ||
| Baseline platelet count | 1.00 (1.00-1.00) | 0.18 |
|
| ||
| Stage | ||
| II | — | |
| III | 2.07 (0.72-5.95) | 0.18 |
| IVA | 4.31 (0.92-20.18) | 0.06 |
| IVB | 2.24 (0.65-7.75) | 0.20 |
|
| ||
| BRCA status | ||
| No mutation | — | |
| BRCA 1/2 | 0.66 (0.32-1.36) | 0.26 |
| Unknown | 1.04 (0.59-1.82) | 0.91 |
|
| ||
| Resection status | ||
| R0 | — | |
| ≤1 cm | 2.28 (1.20-4.34) | 0.01 |
| >1 cm | 2.10 (0.86-5.16) | 0.11 |
|
| ||
| Treatment group | ||
| NACT | — | |
| Primary surgery | 0.69 (0.42-1.14) | 0.14 |
ECOG=Eastern Cooperative Oncology Group, Scope=Laparoscopy, NACT=Neoadjuvant chemotherapy